Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study

Abstract Background Altered regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in type 1 diabetes. We investigated associations between plasma MMP-1, -2, -3, -9, -10 and TIMP-1, a...

Full description

Bibliographic Details
Main Authors: S. A. Peeters, L. Engelen, J. Buijs, A. Jorsal, H.-H. Parving, L. Tarnow, P. Rossing, C. G. Schalkwijk, C. D. A. Stehouwer
Format: Article
Language:English
Published: BMC 2017-04-01
Series:Cardiovascular Diabetology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12933-017-0539-1
id doaj-5ba044e823f841c0bc711ec531ba2476
record_format Article
spelling doaj-5ba044e823f841c0bc711ec531ba24762020-11-25T02:44:16ZengBMCCardiovascular Diabetology1475-28402017-04-0116111210.1186/s12933-017-0539-1Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up studyS. A. Peeters0L. Engelen1J. Buijs2A. Jorsal3H.-H. Parving4L. Tarnow5P. Rossing6C. G. Schalkwijk7C. D. A. Stehouwer8Department of Internal Medicine, Maastricht University Medical CentreDepartment of Internal Medicine, Maastricht University Medical CentreDepartment of Internal Medicine, Zuyderland hospitalDepartment of Cardiology, Aarhus University HospitalDepartment of Medical Endocrinology, RigshospitaletSteno Diabetes CenterSteno Diabetes CenterDepartment of Internal Medicine, Maastricht University Medical CentreDepartment of Internal Medicine, Maastricht University Medical CentreAbstract Background Altered regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in type 1 diabetes. We investigated associations between plasma MMP-1, -2, -3, -9, -10 and TIMP-1, and cardiovascular events and all-cause mortality in type 1 diabetic patients. Methods We prospectively followed 337 type 1 diabetic patients [mean age 41.4 years (9.6), 39% female], 170 with and 167 without diabetic nephropathy, with median follow-up of 12.3 years. Survival analyses were applied to investigate differences in plasma MMP-1, -2, -3, -9, -10, and TIMP-1-levels in patients with and without a cardiovascular event and in those who died vs survivors. All analyses were adjusted for age, sex, duration of diabetes, HbA1c, nephropathy and for other conventional cardiovascular risk factors. Results After adjustment for potential confounders, higher MMP-2 plasma levels were significantly associated with higher incidence of cardiovascular events [HR 1.49 (95% CI 1.11; 1.99)], and higher plasma levels of MMP-1 [1.38 (1.07; 1.78)], MMP-2 [1.60 (1.19; 2.15)] and MMP-3 [1.39 (1.05; 1.85)] were associated with all-cause mortality. All associations were independent of low-grade inflammation and endothelial dysfunction as estimated by plasma markers. Associations between MMP-2 and cardiovascular events and between MMP-3 and mortality were attenuated after further adjustment for eGFR and changes in eGFR. Conclusions Higher levels of MMP-2 are associated with CVD and higher MMP-1, -2 and -3 with all-cause mortality. In addition, associations between MMP-2 and CVD, and MMP-3 and mortality were attenuated after adjustment for eGFR while both MMPs were associated with eGFR decline, indicating a possible mediating role of eGFR.http://link.springer.com/article/10.1186/s12933-017-0539-1Type 1 diabetesCardiovascular diseaseAll-cause mortalityMatrix metalloproteinaseTissue inhibitor of metalloproteinaseEstimated glomerular filtration rate
collection DOAJ
language English
format Article
sources DOAJ
author S. A. Peeters
L. Engelen
J. Buijs
A. Jorsal
H.-H. Parving
L. Tarnow
P. Rossing
C. G. Schalkwijk
C. D. A. Stehouwer
spellingShingle S. A. Peeters
L. Engelen
J. Buijs
A. Jorsal
H.-H. Parving
L. Tarnow
P. Rossing
C. G. Schalkwijk
C. D. A. Stehouwer
Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
Cardiovascular Diabetology
Type 1 diabetes
Cardiovascular disease
All-cause mortality
Matrix metalloproteinase
Tissue inhibitor of metalloproteinase
Estimated glomerular filtration rate
author_facet S. A. Peeters
L. Engelen
J. Buijs
A. Jorsal
H.-H. Parving
L. Tarnow
P. Rossing
C. G. Schalkwijk
C. D. A. Stehouwer
author_sort S. A. Peeters
title Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
title_short Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
title_full Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
title_fullStr Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
title_full_unstemmed Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
title_sort plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
publisher BMC
series Cardiovascular Diabetology
issn 1475-2840
publishDate 2017-04-01
description Abstract Background Altered regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in type 1 diabetes. We investigated associations between plasma MMP-1, -2, -3, -9, -10 and TIMP-1, and cardiovascular events and all-cause mortality in type 1 diabetic patients. Methods We prospectively followed 337 type 1 diabetic patients [mean age 41.4 years (9.6), 39% female], 170 with and 167 without diabetic nephropathy, with median follow-up of 12.3 years. Survival analyses were applied to investigate differences in plasma MMP-1, -2, -3, -9, -10, and TIMP-1-levels in patients with and without a cardiovascular event and in those who died vs survivors. All analyses were adjusted for age, sex, duration of diabetes, HbA1c, nephropathy and for other conventional cardiovascular risk factors. Results After adjustment for potential confounders, higher MMP-2 plasma levels were significantly associated with higher incidence of cardiovascular events [HR 1.49 (95% CI 1.11; 1.99)], and higher plasma levels of MMP-1 [1.38 (1.07; 1.78)], MMP-2 [1.60 (1.19; 2.15)] and MMP-3 [1.39 (1.05; 1.85)] were associated with all-cause mortality. All associations were independent of low-grade inflammation and endothelial dysfunction as estimated by plasma markers. Associations between MMP-2 and cardiovascular events and between MMP-3 and mortality were attenuated after further adjustment for eGFR and changes in eGFR. Conclusions Higher levels of MMP-2 are associated with CVD and higher MMP-1, -2 and -3 with all-cause mortality. In addition, associations between MMP-2 and CVD, and MMP-3 and mortality were attenuated after adjustment for eGFR while both MMPs were associated with eGFR decline, indicating a possible mediating role of eGFR.
topic Type 1 diabetes
Cardiovascular disease
All-cause mortality
Matrix metalloproteinase
Tissue inhibitor of metalloproteinase
Estimated glomerular filtration rate
url http://link.springer.com/article/10.1186/s12933-017-0539-1
work_keys_str_mv AT sapeeters plasmamatrixmetalloproteinasesareassociatedwithincidentcardiovasculardiseaseandallcausemortalityinpatientswithtype1diabetesa12yearfollowupstudy
AT lengelen plasmamatrixmetalloproteinasesareassociatedwithincidentcardiovasculardiseaseandallcausemortalityinpatientswithtype1diabetesa12yearfollowupstudy
AT jbuijs plasmamatrixmetalloproteinasesareassociatedwithincidentcardiovasculardiseaseandallcausemortalityinpatientswithtype1diabetesa12yearfollowupstudy
AT ajorsal plasmamatrixmetalloproteinasesareassociatedwithincidentcardiovasculardiseaseandallcausemortalityinpatientswithtype1diabetesa12yearfollowupstudy
AT hhparving plasmamatrixmetalloproteinasesareassociatedwithincidentcardiovasculardiseaseandallcausemortalityinpatientswithtype1diabetesa12yearfollowupstudy
AT ltarnow plasmamatrixmetalloproteinasesareassociatedwithincidentcardiovasculardiseaseandallcausemortalityinpatientswithtype1diabetesa12yearfollowupstudy
AT prossing plasmamatrixmetalloproteinasesareassociatedwithincidentcardiovasculardiseaseandallcausemortalityinpatientswithtype1diabetesa12yearfollowupstudy
AT cgschalkwijk plasmamatrixmetalloproteinasesareassociatedwithincidentcardiovasculardiseaseandallcausemortalityinpatientswithtype1diabetesa12yearfollowupstudy
AT cdastehouwer plasmamatrixmetalloproteinasesareassociatedwithincidentcardiovasculardiseaseandallcausemortalityinpatientswithtype1diabetesa12yearfollowupstudy
_version_ 1724766683704328192